VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
REGN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
REGNRegeneron Pharmaceuticals, Inc.
$945.53$97.4B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksREGNFinancials

Regeneron Pharmaceuticals, Inc. (REGN) Income Statement

30Y historyFree accessUpdated daily

Revenue and margins have trended sharply higher in the latest quarter, with gross margin reaching 88.8% and operating margin 40.0% in 2026Q3, although prior quarters showed uneven growth of 16.7% and 19.0%, suggesting the improvement may be lumpy rather than steady.

Income StatementBalance SheetCash FlowRatios

REGN Income Statement

Annual statement

REGN Income Statement

Regeneron Pharmaceuticals, Inc. (REGN) annual income statement — 30-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Sales/Revenue16.9B14.34B14.2B13.12B12.17B16.07B8.5B6.56B6.71B5.87B4.86B4.1B2.82B2.1B1.38B445.82M459.07M379.27M238.46M125.02M63.45M66.19M174.02M57.5M21.99M21.97M59.28M34.5M38.2M33.1M24.1M
Revenue Growth %18.59%0.99%8.27%7.76%-24.26%89.14%29.58%-2.28%14.28%20.82%18.44%45.55%33.96%52.69%209.2%-2.89%21.04%59.05%90.73%97.05%-4.15%-61.96%202.65%161.49%0.07%-62.93%71.81%-9.69%15.41%37.34%-12.04%
Cost of Goods Sold2.4B2.1B1.97B2.24B1.71B2.72B1.36B975.4M582.3M542.53M404.44M467.62M257.7M196.56M121.39M35.3M21.78M15.93M12.21M022.74M25.06M151.31M6.68M6.48M6.51M15.57M3.6M5M2.6M1.1M
COGS % of Revenue-14.65%13.87%17.11%14.01%16.95%15.96%14.87%8.68%9.24%8.32%11.39%9.14%9.34%8.81%7.92%4.74%4.2%5.12%-35.84%37.86%86.95%11.61%29.48%29.62%26.26%10.43%13.09%7.85%4.56%
Gross Profit14.49B12.24B12.23B10.87B10.47B13.35B7.14B5.58B6.13B5.33B4.46B3.64B2.56B1.91B1.26B410.53M437.29M363.33M226.25M040.71M41.13M22.71M50.82M15.51M15.46M43.71M30.9M33.2M30.5M23M
Gross Margin %85.77%85.35%86.13%82.89%85.99%83.05%84.04%85.13%91.32%90.76%91.68%88.61%90.86%90.66%91.19%92.08%95.26%95.8%94.88%-64.16%62.14%13.05%88.39%70.52%70.38%73.74%89.57%86.91%92.14%95.44%
Gross Profit Growth %-0.09%12.5%3.87%-21.58%86.91%27.93%-8.91%14.99%19.61%22.55%41.93%34.26%51.79%206.21%-6.12%20.36%60.59%--100%-1.03%81.13%-55.32%227.77%0.27%-64.62%41.46%-6.93%8.85%32.61%-16.06%
Operating Expenses9.5B8.66B8.24B6.52B5.08B4.4B3.56B3.37B3.59B3.25B3.13B2.38B1.72B1.15B796.57M615.68M534.77M437.44M316.08M227.99M148.02M163.34M17.06M150.81M137.46M101.15M68.99M54.7M45.8M38M40.3M
OpEx % of Revenue-60.41%58.03%49.74%41.75%27.38%41.95%51.43%53.56%55.35%64.3%58.1%61.12%54.53%57.79%138.1%116.49%115.34%132.55%182.36%233.29%246.76%9.8%262.29%625.15%460.32%116.38%158.55%119.9%114.8%167.22%
Selling, General & Admin2.76B2.7B2.95B2.54B2.12B1.82B1.35B1.34B1.56B1.32B1.18B838.53M504.75M328.92M207.96M117.26M65.2M52.92M49.35M37.87M25.89M25.42M17.06M14.79M12.53M9.61M8.31M6.4M5.8M5.8M5.9M
SG&A % of Revenue-18.82%20.8%19.36%17.38%11.35%15.84%20.46%23.19%22.49%24.23%20.43%17.9%15.63%15.09%26.3%14.2%13.95%20.69%30.29%40.81%38.4%9.8%25.71%56.99%43.72%14.02%18.55%15.18%17.52%24.48%
Research & Development6.72B5.85B5.23B3.99B3.06B2.62B2.5B2.24B2.04B1.93B1.95B1.55B1.22B818.74M588.61M498.42M469.56M384.51M266.73M190.13M122.12M137.92M136.09M136.02M124.93M91.54M56.26M44.9M37M27.8M28.3M
R&D % of Revenue-40.79%36.85%30.39%25.11%16.31%29.41%34.15%30.37%32.86%40.07%37.66%43.22%38.9%42.7%111.8%102.29%101.38%111.86%152.07%192.48%208.36%78.21%236.58%568.16%416.6%94.91%130.14%96.86%83.99%117.43%
Other Operating Expenses1000K114.1M53.4M-2.1M-89.9M-45.6M-280.4M-209.2M0000-1.2B-801.26M0000011.49M00-136.09M0004.42M3.4M3M4.4M6.1M
Operating Income4.99B3.58B3.99B4.35B5.39B8.95B3.58B2.21B2.53B2.08B1.33B1.25B823.92M743.05M460.51M-205.16M-97.47M-74.1M-89.83M-114.45M-107.31M-124.42M5.65M-99.99M-121.95M-85.68M-25.28M-23.8M-12.5M-7.5M-17.3M
Operating Margin %29.54%24.95%28.1%33.15%44.24%55.67%42.09%33.7%37.77%35.41%27.38%30.51%29.22%35.3%33.41%-46.02%-21.23%-19.54%-37.67%-91.55%-169.13%-187.97%3.24%-173.9%-554.63%-389.95%-42.64%-68.99%-32.72%-22.66%-71.78%
Operating Income Growth %--10.34%-8.23%-19.26%-39.8%150.15%61.85%-12.81%21.87%56.27%6.3%51.95%10.88%61.35%324.47%-110.48%-31.54%17.51%21.51%-6.66%13.75%-2303.7%105.65%18.01%-42.33%-238.99%-6.2%-90.4%-66.67%56.65%-127.63%
EBITDA5.5B4.12B4.47B4.77B5.73B9.23B3.81B2.42B2.68B2.23B1.44B1.33B876.61M784.25M497.45M-174.08M-77.78M-59.86M-78.54M-102.97M-92.72M-108.92M21.01M-87.05M-113.5M-79.61M-20.86M-20.4M-9.5M-3.1M-11.2M
EBITDA Margin %32.58%28.74%31.5%36.36%47.05%57.45%44.87%36.91%39.97%37.89%29.53%32.33%31.09%37.26%36.09%-39.05%-16.94%-15.78%-32.94%-82.36%-146.13%-164.54%12.07%-151.4%-516.19%-362.29%-35.18%-59.13%-24.87%-9.37%-46.47%
EBITDA Growth %30.64%-7.87%-6.21%-16.72%-37.97%142.18%57.53%-9.79%20.56%55%8.19%51.36%11.78%57.65%385.77%-123.79%-29.95%23.79%23.72%-11.06%14.88%-618.45%124.13%23.3%-42.58%-281.71%-2.23%-114.74%-206.45%72.32%-558.82%
D&A (Non-Cash Add-back)512.9M543.7M482.9M421M341.4M286.2M235.9M210.3M148.2M145.47M104.75M74.91M52.69M41.2M36.94M31.08M19.69M14.25M11.29M11.49M14.59M15.5M15.36M12.94M8.45M6.08M4.42M3.4M3M4.4M6.1M
EBIT5.73B5.27B4.84B4.27B4.92B9.38B3.87B2.46B2.58B2.1B1.34B1.24B813.12M759.8M459.73M-201.61M-95.35M-69.61M-72.61M-93.56M-91.11M-83.4M53.87M-99.99M-121.95M-85.68M-25.28M-23.8M-12.5M-13.7M-17.3M
Net Interest Income695.2M673M656.2M422.9M100.7M-57.3M-56.9M-30.2M-28.2M-25.12M-7.2M-7.96M-31.61M-43.77M-43.29M-17.73M-7.1M2.05M12.91M14.75M4.5M-1.67M-6.7M00000000
Interest Income741.9M716.8M711.4M495.9M160.1M0000006.28M5.76M2.67M2.01M3.55M2.02M4.39M20.66M26.8M16.55M10.38M5.48M00000000
Interest Expense46.7M43.8M55.2M73M59.4M57.3M56.9M30.2M28.2M25.12M7.2M14.24M37.37M46.44M45.3M21.28M9.12M2.34M7.75M12.04M0000004.58M003.4M14.3M
Other Income/Expense695.3M1.65B789.2M-149.3M-526.8M379M233.8M219.3M19.1M-1.08M-926K-26.82M-62.68M-47.17M-46.09M-17.73M-7M2.15M9.47M8.85M4.16M26.76M36.05M-7.47M-2.42M9.5M25.28M23.8M12.5M6.2M0
Pretax Income5.69B5.23B4.78B4.2B4.86B9.33B3.81B2.43B2.55B2.08B1.33B1.23B775.75M713.36M414.42M-222.89M-104.47M-71.95M-80.36M-93.56M-91.11M124.42M53.87M-95.53M-112.52M-73.52M-29.85M-22.8M-8.2M-7.5M-17.3M
Pretax Margin %33.66%36.47%33.66%32.01%39.91%58.03%44.84%37.04%38.05%35.4%27.36%29.85%27.51%33.89%30.06%-50%-22.76%-18.97%-33.7%-74.83%-143.6%187.97%30.96%-166.14%-511.72%-334.61%-50.36%-66.09%-21.47%-22.66%-71.78%
Income Tax869.4M725.8M367.3M245.7M520.4M1.25B297.2M313.3M109.1M880M434.29M589.04M427.67M289M-335.85M-1.13M0-4.12M2.35M-29.75M-21.87M178.85M-84.28M3.01M-7.01M-21.66M2.51M-1.7M-8.4M7.5M29.4M
Effective Tax Rate %15.29%13.88%7.68%5.85%10.71%13.41%7.8%12.9%4.27%42.34%32.66%48.08%55.13%40.51%-81.04%0.51%0%5.73%-2.93%31.8%24%143.74%-156.44%-3.15%6.23%29.46%-8.42%7.46%102.44%-100%-169.94%
Net Income4.82B4.5B4.41B3.95B4.34B8.08B3.51B2.12B2.44B1.2B895.52M636.06M348.07M424.36M750.27M-221.76M-104.47M-67.83M-82.71M-105.6M-102.34M-95.45M41.7M-107.46M-124.38M-76.18M-23.21M-23.1M-8.6M-11.6M-32.4M
Net Margin %28.51%31.41%31.07%30.14%35.64%50.25%41.35%32.26%36.42%20.41%18.42%15.5%12.35%20.16%54.43%-49.74%-22.76%-17.88%-34.69%-84.46%-161.3%-144.19%23.96%-186.89%-565.66%-346.7%-39.16%-66.96%-22.51%-35.05%-134.44%
Net Income Growth %5.23%2.09%11.61%-8.87%-46.28%129.86%66.05%-13.44%103.95%33.83%40.79%82.74%-17.98%-43.44%438.32%-112.28%-54.01%17.99%21.68%-3.19%-7.22%-328.89%138.8%13.6%-63.27%-228.15%-0.5%-168.6%25.86%64.2%-37.87%
Net Income (Continuing)4.82B4.5B4.41B3.95B4.34B8.08B3.51B2.12B2.44B1.2B895.52M636.06M338.13M413.74M750.27M-221.76M-104.47M-67.83M-82.71M-105.6M-103.15M-95.45M41.7M-107.46M-124.38M-76.18M-21.65M-23.1M-8.6M-11.6M-32.4M
Discontinued Operations0000000000000000000000000000000
Minority Interest0000000000000000000000000000000
EPS (Diluted)45.6241.4838.3434.7738.2271.9730.5218.4621.2910.347.705.522.983.726.75-2.45-1.26-0.85-1.05-1.59-1.77-1.710.74-2.13-2.83-1.81-0.66-0.73-0.28-0.40-1.32
EPS Growth %8.38%8.19%10.27%-9.03%-46.89%135.81%65.33%-13.29%105.9%34.29%39.49%85.23%-19.89%-44.89%375.51%-94.44%-48.24%19.05%33.96%10.17%-3.51%-331.08%134.74%24.73%-56.35%-174.24%9.59%-160.71%30%69.7%-10.92%
EPS (Basic)-43.0740.9037.0540.5176.4032.6519.3821.2911.278.556.173.364.237.92-2.45-1.26-0.85-1.05-1.59-1.77-1.710.75-2.13-2.83-1.81-0.66-0.74-0.28-0.40-1.32
Diluted Shares Outstanding105.6M108.6M115.1M113.7M113.5M112.2M115.1M114.6M114.8M115.91M116.3M115.23M113.47M111.29M115.38M90.61M82.93M79.78M78.83M66.33M57.97M55.95M56.17M50.45M43.95M42.09M35.17M31.45M31M29M24.46M
Basic Shares Outstanding101.7M104.6M107.9M106.7M107.1M105.7M107.6M109.2M114.8M115.9M116.25M115.23M113.41M111.22M111.07M90.61M82.93M79.78M78.83M66.33M57.97M55.95M55.42M50.45M43.95M42.09M35.17M31.22M30.71M29M24.46M
Dividend Payout Ratio-8.22%-----------------------------

Key Metrics

Growth RegimeMixed
ProfitabilityModerate
Balance SheetHealthy
Cash FlowStable
Top Statement Risk

Revenue concentration and volatile quarterly earnings

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Lumpy Revenue Growth Masks Recent Acceleration

Based on REGN's reported quarterly figures, revenue grew 36.3% year-over-year in 2026Q3 to $5.1B, but the prior two quarters showed much weaker growth of 16.7% and 19.0%, suggesting growth is uneven rather than steadily compounding.

The pattern from 2024 through 2025 shows revenue hovering between $3.0B and $3.9B with growth rates swinging from negative to low single digits, which points to a business where timing of large product or collaboration recognitions drives the top line. The 2026Q3 step-up implies a meaningful discrete driver, and investors should monitor whether it reflects recurring product demand or a one-time recognition. Durability cannot be judged until a second consecutive quarter confirms the new revenue level.

Gross Margin Expansion Reflects Mix Shift

As reported in financial statements, REGN's gross margin rose from roughly 81% in 2026Q1 to 88.8% in 2026Q3, approaching the 85% to 93% range of higher-margin biotech peers such as VRTX and INCY.

The high gross margin structure is consistent with a product-driven revenue base where cost of goods is a small fraction of sales, typical of branded biologics. The expansion from the low 80s toward high 80s suggests a favorable product mix or pricing shift rather than cost reduction alone, though the data alone cannot isolate which. Because cyclicality in quarterly revenue flows directly into margin volatility, the sustainability of the 2026Q3 level warrants further investigation.

Operating Leverage Visible but Uneven

Based on REGN's reported figures, operating income rose from $642.9M in 2026Q1 to $2.0B in 2026Q3, a tripling that outpaced the roughly 42% revenue increase over the same span, indicating strong operating leverage in the latest quarter.

SG&A stayed relatively contained at about $650M to $680M per quarter across the recent period while revenue moved materially, which explains why incremental revenue dropped disproportionately to operating profit. R&D spending of roughly $1.6B per quarter remains a large fixed burden, so operating margin is highly sensitive to whether revenue holds at the new level. The operating leverage cuts both ways, and a revenue decline would compress margins quickly.

Net Income Exceeds Operating Income Repeatedly

According to reported quarterly data, REGN's net income exceeded operating income in several periods, including $1.9B against $2.0B in 2026Q3 and $1.3B against $1.0B in 2025Q3, indicating that non-operating items or tax effects contribute materially to reported earnings.

In 2025Q3 net income of $1.5B surpassed operating income of $1.0B by a wide margin, a gap that the supplied data does not explain and that could reflect investment gains, interest income, or tax benefits. Earnings derived substantially from non-operating sources are generally less repeatable than operating profit, so analysts should separate the two before extrapolating. Stock-based compensation of roughly $240M to $300M per quarter is material and should be weighed against reported EPS.

R&D Burden Dominates the Cost Base

As reported in financial statements, REGN's R&D expense held near $1.6B per quarter across 2025 and 2026, representing roughly 30% to 40% of revenue and the largest single cost line after cost of goods.

Sustained R&D at this scale reflects a pipeline-dependent model where spending is committed well ahead of revenue, which limits flexibility when sales soften. SG&A at around $650M to $790M per quarter appears comparatively disciplined relative to the revenue base, suggesting management has held overhead growth below top-line growth. Whether this R&D level is productive is a question the income statement alone cannot answer.

Lumpy Revenue Could Reverse Quickly

Based on REGN's reported quarterly history, revenue fell to $3.0B in 2025Q1 after reaching $3.8B in 2024Q3, showing that a single weak quarter can erase months of gains and undermine the margin expansion narrative.

The bear case centers on whether the 2026Q3 revenue spike is non-recurring, since the prior eight quarters show no sustained upward trend. If revenue reverts toward the $3.5B to $3.8B range, the fixed R&D base of about $1.6B per quarter would compress operating margin sharply from 40% toward the low 20s. Investors should monitor whether subsequent quarters confirm the new run rate before assuming durable profitability.

REGN — Frequently Asked Questions

Quick answers to the most common questions about buying REGN stock.

What was Regeneron Pharmaceuticals, Inc.'s (REGN) revenue in 2025?

For fiscal year 2025, Regeneron Pharmaceuticals, Inc. (REGN) reported total revenue of $14.34B. This represents a 59414.1% increase compared to $24.1M in 1996.

Is Regeneron Pharmaceuticals, Inc. (REGN) profitable?

Regeneron Pharmaceuticals, Inc. (REGN) is profitable, generating $4.50B in net income for the fiscal year ending 2025 with a net profit margin of 31.4%.

What is Regeneron Pharmaceuticals, Inc.'s operating profit margin?

Regeneron Pharmaceuticals, Inc. (REGN) reported an operating income of $3.58B, resulting in an operating profit margin of 24.9%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Regeneron Pharmaceuticals, Inc.'s gross profit and gross margin?

Regeneron Pharmaceuticals, Inc. (REGN) generated $12.24B in gross profit for the year, representing a gross profit margin of 85.4%. This demonstrates the company's core pricing power and production efficiency.